years from children initially two to seven years of age. No conversions from negative to positive were noted and in six children having the antibody, the titers remained at constant levels from the first to last serum specimen. From the Cleveland study, 12 sets of sera became available from children ranging in age from 1 day to 8 years at the time of the first bleeding and observed for periods between 5 and 14 years. Nine of these children remained free of antibodies to EBV throughout the observation periods, at the end of which their ages ranged from 7 to 17 years. Two children, both 5 years old, possessed antibodies at the start, and the titers persisted at nearly constant levels (1: 20-1:80) for 10 and 12 years, respectively. The 12th child (4-5, Table 1) revealed antibodies at birth, none in the next two sera. Between 2'/2 and 31/3 years of age, the reaction became positive, and the titers remained stable at 1: 80 for the subsequent 6 years. In the 10-month period in which the antibody appeared, the child sustained three common colds, a gastroenteritis, and on September 2, 1951 a "nonbacterial tonsillitis" of 6 days' duration. The frequency in children of antibodies to EBV, both in the New York and Cleveland studies, was small in comparison to the much higher incidence of positive reactions (about 50%) among sera from randomly selected patients, aged [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] years, at the Children's Hospital of Philadelphia.'8 This difference presumably reflects the fact that the hospital patients came largely from low socioeconomic levels, whereas the prospective studies involved well-to-do families.
An additional lead in the search for EBV-induced illnesses developed as a result of the following experience. E. H., a research technician in this laboratory, had contributed peripheral leukocytes in January 1967 for the type of experiment described in a preliminary report.11 Planted on monolayers of human diploid cells (WI-38), her cells failed to grow at that time, and her plasma was devoid of antibodies to EBV ( of especial value since they were derived from a prospective study of IM in which baseline sera were obtained from students on entry into school, with the expectation that some of them would subsequently contract the disease. Table 3 shows the distribution of anti-EBV titers among acute stage sera of IM patients. All sera were strongly positive, with titers as high as 1:1280. Of 50 baseline sera of Yale students, 10 randomly selected from each of 5 consecutive years, only 24 per cent were positive, and their titers did not exceed 1: 80. The low percentage of reactive sera may be a reflection of the socioeconomic level of their donors, as mentioned earlier. Results obtained with sera from patients with Burkitt's lymphomas and from African control children are included in the table for comparison. While only about half of the control sera gave reactions, mostly at low titers, all of the Burkitt's tumor patients possessed antibodies to EBV, and the distribution of titers among their sera was similar to that seen with IM cases. The IM patients generally also showed high heterophile antibody levels, whereas the sera of the Burkitt's patients tested were negative. The table also includes results obtained with sera from five American and nine African patients with carcinomas of the postnasal space. Twelve of 14 revealed titers in the ranges seen with IM and Burkitt's patients.
The fact that all acute stage sera from IM patients contained antibodies to Discussion.-The evidence strongly implies that EB virus is etiologically related to infectious mononucleosis. This conclusion is supported by the fact that all patients thus far studied showed high levels of anti-EBV in their acute stage sera, whereas only 24 per cent of sera from an appropriate control group reacted, and then, as a rule, to lower titers. Preinfection sera, available from 12 of the patients, were all negative and some of these had been collected only 1-3 months prior to onset of the disease. Furthermore, five of the patients revealed rises in antibodies from the first to subsequent acute stage sera, indicative of a current EBV infection. The titers tended to decline slightly as time progressed, but evidence provided by children of the Cleveland Family Study suggests that they may persist for many years. Sera from individuals with histories of IM as long as 20 years ago revealed anti-EBV levels of 1:40 to 1:80.
One might speculate that IM activates a latent EBV infection and that therefore the agent is unrelated to IM. This appears unlikely because of the apparent persistence of antibodies to EBV and none of the baseline sera revealed even traces of reactivity. Furthermore, such a situation would not be expected to exist in 100 per cent of the patients. The same arguments also hold against the suggestion of an anamnestic antibody response. In addition, such recalls are usually more rapid than the rate of anti-EBV formation as observed, for instance, in patients A and L. It should be noted, too, that antibodies to herpes simplex virus remained stationary in the course of IM and that anti-EBV levels failed to fluctuate in patients with infectious or serum hepatitis.
The available information on EBV and its seroepidemiology seems to fit well with what is known about infectious mononucleosis. The virus appears to depend upon cells of the hematopoietic system for its replication. IM cultures, whereas X-irradiated EBV-free Burkitt's tumor cells had no such growth-stimulating effect."I The leukocyte cultures so obtained had acquired a persistent infection by EBV, and many of the cells revealed the chromosomal marker previously observed in Burkitt's tumor cell lines20 and now also found in cultured E. H. cells. While these results do not indicate oncogenicity of EBV, they certainly do not preclude the possibility.
Summary.-Patients with infectious mononucleosis regularly develop antibodies to the herpes-type virus (EBV) found in cultures derived from Burkitt's tumors or other cells of the hematopoietic system. The antibodies persist for many years and are distinct from heterophile antibodies. The epidemiology of IM and the seroepidemiology of EBV share many features. Thus, it appears that EBV, or a close relative of it, is the cause of IM. This conclusion does not preclude the possibility that EBV might also be involved, either directly or indirectly, in the etiology of Burkitt's lymphoma.
